Market closed
Vir Biotechnology/$VIR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Vir Biotechnology
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Ticker
$VIR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
587
Website
VIR Metrics
BasicAdvanced
$928M
Market cap
-
P/E ratio
-$3.93
EPS
0.45
Beta
-
Dividend rate
Price and volume
Market cap
$928M
Beta
0.45
52-week high
$13.09
52-week low
$6.62
Average daily volume
1.3M
Financial strength
Current ratio
8.938
Quick ratio
7.851
Long term debt to equity
7.528
Total debt to equity
9.092
Management effectiveness
Return on assets (TTM)
-19.40%
Return on equity (TTM)
-36.58%
Valuation
Price to revenue (TTM)
11.633
Price to book
0.74
Price to tangible book (TTM)
0.76
Price to free cash flow (TTM)
-1.933
Growth
Revenue change (TTM)
-33.83%
Earnings per share change (TTM)
-12.44%
3-year revenue growth (CAGR)
-34.86%
3-year earnings per share growth (CAGR)
70.04%
What the Analysts think about VIR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Vir Biotechnology stock.
VIR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
VIR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
VIR News
AllArticlesVideos
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Business Wire·3 days ago
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
Business Wire·4 days ago
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
Business Wire·7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Vir Biotechnology stock?
Vir Biotechnology (VIR) has a market cap of $928M as of November 22, 2024.
What is the P/E ratio for Vir Biotechnology stock?
The price to earnings (P/E) ratio for Vir Biotechnology (VIR) stock is 0 as of November 22, 2024.
Does Vir Biotechnology stock pay dividends?
No, Vir Biotechnology (VIR) stock does not pay dividends to its shareholders as of November 22, 2024.
When is the next Vir Biotechnology dividend payment date?
Vir Biotechnology (VIR) stock does not pay dividends to its shareholders.
What is the beta indicator for Vir Biotechnology?
Vir Biotechnology (VIR) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.